Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
98 GBX | -1.51% | -4.85% | +12.64% |
Apr. 02 | Roadside shares suspended; Adnams looks for funds | AN |
Mar. 21 | Diaceutics upgrades diagnositc commercialisation platform, DXRX | AN |
Sales 2023 * | 23.89M 29.96M | Sales 2024 * | 29.61M 37.14M | Capitalization | 82.76M 104M |
---|---|---|---|---|---|
Net income 2023 * | -1M -1.25M | Net income 2024 * | -2M -2.51M | EV / Sales 2023 * | 2.79 x |
Net cash position 2023 * | 16.13M 20.23M | Net cash position 2024 * | 13.48M 16.91M | EV / Sales 2024 * | 2.34 x |
P/E ratio 2023 * |
-58.1
x | P/E ratio 2024 * |
-51.9
x | Employees | 151 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 65.46% |
Latest transcript on Diaceutics PLC
1 day | -1.51% | ||
1 week | -4.85% | ||
Current month | -1.01% | ||
1 month | -6.67% | ||
3 months | +1.03% | ||
6 months | +13.95% | ||
Current year | +12.64% |
Managers | Title | Age | Since |
---|---|---|---|
Ryan Keeling
CEO | Chief Executive Officer | 40 | 08-05-31 |
Nick Roberts
DFI | Director of Finance/CFO | - | 22-03-17 |
Julie Browne
COO | Chief Operating Officer | - | 22-03-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Graham Paterson
BRD | Director/Board Member | - | 23-09-30 |
Deborah Davis
CHM | Chairman | 61 | 21-01-03 |
Peter Keeling
BRD | Director/Board Member | 63 | 04-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 98 | -1.51% | 62,677 |
24-05-02 | 99.5 | 0.00% | 5,402 |
24-05-01 | 99.5 | +0.51% | 76,012 |
24-04-30 | 99 | -3.88% | 103,776 |
24-04-29 | 103 | 0.00% | 1,625 |
Delayed Quote London S.E., May 03, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.64% | 104M | |
-28.43% | 2.06B | |
+24.23% | 1.94B | |
+8.86% | 1.72B | |
-4.23% | 1.69B | |
-16.17% | 1.59B | |
-24.70% | 1.37B | |
-4.99% | 1.2B | |
-4.66% | 1.05B | |
+119.33% | 694M |
- Stock Market
- Equities
- DXRX Stock